Opinion|Videos|March 14, 2025
Maria's Patient Journey: Clinical Trial Experience
Author(s)Arash Mostaghimi, MD, MPH, Brett King, MD, PhD
A panelist discusses how ritlecitinib can be recommended for alopecia areata after previous treatments proved ineffective, initially raising questions about the medication's safety profile, potential adverse effects, and realistic timeline for hair regrowth.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When did Dr King talk to you about starting ritlecitinib to treat your alopecia areata?
- What were your initial thoughts and questions when you first heard about the treatment?
Advertisement
Related to this article
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
3
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
4
EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know
5